| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
ATH686 is a novel and selective FLT3 Inhibitor. ATH686 is part of a novel class of extremely powerful FLT3 inhibitors that can overcome drug resistance in a way that less powerful "type I" and "type II" first-generation FLT3 inhibitors are unable to.
| ln Vitro |
ATH686 (1-100 µM; 3 days) induces apoptosis in FLT3-ITD-Ba/F3 and D835Y-Ba/F3 cells, thereby potently inhibiting cell proliferation (IC50 approximately 0.001 µM)[1].
ATH686 (10 nM) inhibits the autophosphorylation of mutant FLT3 for a duration of 15 minutes in FLT3-ITD-Ba/F3 cells[1]. |
|---|---|
| Cell Assay |
Cell Line: FLT3-ITD-Ba/F3 cells and D835Y-Ba/F3 cells
Concentration: 1, 5, 10, 50, 100 µM Incubation Time: 3 days Result: Potently inhibited cell proliferation (IC50 around 0.001 µM) via induction of apoptosis. |
| References |
| Molecular Formula |
C25H28F3N7O2
|
|---|---|
| Molecular Weight |
515.5412
|
| Exact Mass |
515.226
|
| Elemental Analysis |
C, 58.24; H, 5.47; F, 11.06; N, 19.02; O, 6.21
|
| CAS # |
853299-52-2
|
| Related CAS # |
853299-52-2
|
| PubChem CID |
11477833
|
| Appearance |
White to light brown solid powder
|
| LogP |
5.254
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
715
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(NC1C=C(C(F)(F)F)C(CN2CCN(CC)CC2)=CC=1)NC1C=CC(OC2C=CN=C(N)N=2)=CC=1
|
| InChi Key |
VQQRBBFRJRBWPF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H28F3N7O2/c1-2-34-11-13-35(14-12-34)16-17-3-4-19(15-21(17)25(26,27)28)32-24(36)31-18-5-7-20(8-6-18)37-22-9-10-30-23(29)33-22/h3-10,15H,2,11-14,16H2,1H3,(H2,29,30,33)(H2,31,32,36)
|
| Chemical Name |
1-[4-(2-aminopyrimidin-4-yl)oxyphenyl]-3-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]urea
|
| Synonyms |
ATH 686; ATH686; ATH-686
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~250 mg/mL (~484.9 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9397 mL | 9.6986 mL | 19.3971 mL | |
| 5 mM | 0.3879 mL | 1.9397 mL | 3.8794 mL | |
| 10 mM | 0.1940 mL | 0.9699 mL | 1.9397 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
